Onychomycosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

 Breaking News
  • No posts were found

Onychomycosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

February 02
18:38 2021
Onychomycosis Market Analysis, Leading Companies, Emerging Drugs and Epidemiology Forecast

Delveinsight Business Research LLP

DelveInsight’s “Onychomycosis Market Insights, Epidemiology, and Market Forecast 2030” report delivers an in-depth understanding of the Onychomycosis, historical and forecasted epidemiology as well as the Onychomycosis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Onychomycosis, a fungal infection of the nail, is the most common nail infection worldwide, causing discolouration and thickening of the affected nail plate. Onychomycosis was initially thought to be caused by dermatophytes predominantly; however, new research has revealed that mixed infections and those caused by nondermatophyte molds (NDMs) are more prevalent than thought previously, especially in warmer climates.

In Western countries, 80–90% of onychomycosis cases are primarily caused by dermatophytes, with 5–17% due to yeasts and 2–3% due to NDMs. The high prevalence of fungal infections in North America is largely due to the immigration of dermatophytes from other areas of the world, such as West Africa and Southeast Asia.

Get FREE sample copy at: 

The Onychomycosis market report also covers emerging drugs, current treatment practices, Onychomycosis market share of the individual therapies, current and forecasted Onychomycosis Market Size from 2017 to 2030 segmented by seven major markets. 

The report provides a detailed current Onychomycosis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market. 

Onychomycosis Market

Onychomycosis Market Key Facts

In 2017, the prevalent population of Onychomycosis in the United States was found to be 35,829,110.

As per Delveinsight’s estimates, the total prevalent cases for Onychomycosis were highest in the United States, followed by Japan and France. Spain accounted for the least number of prevalent cases among the 7MM.

Adults and elderly are more likely to suffer from Onychomycosis when compared to children and adolescents.

The United States accounted for the largest market size of Onychomycosis, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain), and Japan.

 Key Benefits of Onychomycosis Market Report

  • Onychomycosis market report provides an in-depth analysis of Onychomycosis Market Size, Share, Trend, Epidemiology and Market Forecast till 2030, in 7 major market i.e. EU5 (Germany, Italy, Spain, France and the UK), Japan, and the United States.

  • The Onychomycosis market report will help in developing business strategies by understanding the Onychomycosis Market trends & developments, key players and future market competition that will shape and drive the Onychomycosis market in the upcoming years.

  • The Onychomycosis market report covers Onychomycosis current treatment practices, emerging drugs, market share of the individual therapies in 7 MM.

  • The report provides a detailed assessment of the Onychomycosis market in terms of market drivers & barriers, Unmet Needs, market opportunities, patient population,  comparative analysis of pipeline products with detailed clinical profiles, and other factors. 

Onychomycosis Market
Onychomycosis market size is expected to increase during the forecast period owing to the increasing prevalent population of Onychomycosis patients in the 7MM, along with the expected entry of new therapies into the market.

The Onychomycosis market outlook section of the report helps to build the detailed comprehension of the historic, current and forecasted Onychomycosis market trends by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand for better technology. 

The report gives a thorough detail of Onychomycosis market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria, mechanism of action, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, and view of the key opinion leaders. 

Onychomycosis Epidemiology
The Onychomycosis epidemiology section covers insights about historical and current Onychomycosis patient pool and forecasted trends for every seven major countries (i.e. the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom), and Japan from 2017 to 2030.

It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides the diagnosed patient pool and their trends along with assumptions undertaken.  

Onychomycosis Drugs Uptake and Key Market Players
The Onychomycosis Drugs Uptake section focuses on the rate of uptake of the potential drugs recently launched in the Onychomycosis market or expected to get launched in the market during the study period. The analysis covers Onychomycosis market uptake by drugs; patient uptake by therapies; and sales of each drug.    

Report’s Drugs Uptake section helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allow the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions.

The goals of onychomycosis therapy are to both eliminate the infecting fungal organism and restore the nail to its normal state as it grows. Many potential therapies are being investigated for the management of onychomycosis, and the treatment space will experience significant reconstitution during the forecast period.

The key players in the Onychomycosis market include:
Moberg Pharma
Blueberry Therapeutics
Mycovia Pharmaceuticals
And others.

Onychomycosis therapies covered in the report include:
And many more.

Table of Content

1. Key Insights

2. Executive Summary 

3. Onychomycosis Competitive Intelligence Analysis

4. Onychomycosis Market Overview at a Glance

5. Onychomycosis Disease Background and Overview

6. Onychomycosis Patient Journey

7. Onychomycosis Epidemiology and Patient Population

8. Onychomycosis Treatment Algorithm, Current Treatment, and Medical Practices

9. Onychomycosis Unmet Needs

10. Key Endpoints of Onychomycosis Treatment

11. Onychomycosis Marketed Products

12. Onychomycosis Emerging Therapies

13. Onychomycosis Seven Major Market Analysis

14. Attribute Analysis

15. Onychomycosis Market Outlook (7 major markets)

16. Onychomycosis Access and Reimbursement Overview

17. KOL Views on the Onychomycosis Market.

18. Onychomycosis Market Drivers

19. Onychomycosis Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

Related Reports
Onychomycosis Epidemiology Forecast
DelveInsight’s Onychomycosis – Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Onychomycosis.

Onychomycosis Pipeline Insights
Onychomycosis Pipeline Insight, 2020 report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Onychomycosis market.

 About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research Firm focused exclusively on life sciences. It supports pharma companies by providing end to end comprehensive solutions to improve their performance.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Shruti Thakur
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd. 2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Related Articles